Phage therapy for the treatment of human intestinal bacterial infections: soon to be a reality?

Expert Review of Gastroenterology and Hepatology

Volumn 11, Issue 9, 2017, Pages 785-788

  Brüssow, Harald ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

antibiotic resistance; bacterial infections; Bacteriophages; clinical trials; phage therapy

Indexed keywords

TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BANGLADESH; BURN; CHOLERA; DIARRHEA; DYSENTERY; EDITORIAL; ESCHERICHIA COLI INFECTION; GEORGIA (REPUBLIC); HUMAN; INDIA; INTESTINE INFECTION; NONHUMAN; PERSONALIZED MEDICINE; PHAGE THERAPY; POLAND; VIBRIOPHAGE; ANIMAL; BACTERIOPHAGE; ENTEROPATHY; EUROPE; GENETICS; GENOTYPE; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BACTERIAL INFECTIONS; BACTERIOPHAGES; BANGLADESH; EUROPE; GENOTYPE; HUMANS; INDIA; INTESTINAL DISEASES; PHAGE THERAPY; TREATMENT OUTCOME;

EID: 85021176813     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2017.1342534     Document Type: Editorial

References (31)

1. D’Herelle F., Sur un microbe invisible antagoniste des bacilles dysentériques. C R Acad Sci Paris. 1917;165:373–375. (in French).
2. Häusler T., Viruses vs. superbugs. London:Palgrave Macmillan; 2006.
3. Babalova EG, Katsitadze KT, Sakvaredidze LA, et al. Preventive value of dried dysentery bacteriophage. Zh Mikrobiol Epidemiol Immunobiol. 1968;2:143–145.(In Russian) English translation in supplementary data to:McCallin S and Brüssow H. Phage therapy:an alternative or adjunct to antibiotics. Emerging Topics in Life Sciences 2017, in press.
4. Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45:649–659.•• An excellent overview about a large, successful, carefully designed, randomized, and controlled clinical trial on diarrhea prevention conducted in the 1960s by the Eliava Institute in the Soviet Union.
5. D’Herelle F. Studies upon Asiatic cholera. Yale J Biol Med. 1929;1:195–219.•• A fascinating publication allowing insight into the way of thinking and conducting research by a pioneer of microbiology.
6. Summers WC. Cholera and plague in India:the bacteriophage inquiry of 1927–1936. J Hist Med Allied Sci. 1993;48:275–301.
7. Pollitzer R. Cholera studies. 5. Bacteriophage investigations. Bull. 1955;13:1–25. WHO.
8. Faruque SM, Naser IB, Islam MJ, et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc Natl Acad Sci USA. 2005;102:1702–1707.
9. Faruque SM, Islam MJ, Ahmad QS, et al. Self-limiting nature of seasonal cholera epidemics:role of host-mediated amplification of phage. Proc Natl Acad Sci USA. 2005;102:6119–6124.
10. Sayamov RM. Treatment and prophylaxis of cholera with bacteriophage. Bull WHO. 1963;28:361–367.
11. Monsur KA, Rahman MA, Huq F, et al. Effect of massive doses of bacteriophage on excretion of vibrios, duration of diarrhoea and output of stools in acute cases of cholera. Bull World Health Organ. 1970;42(5):723–732.
12. Marcuk LM, Nikiforov VN, Scerbak JF, et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull World Health Organ. 1971;45(1):77–83.
13. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol. 1987;133:1111–1126.
14. Huff WE, Huff GR, Rath NC, et al. Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray. Poult Sci. 2002;81:1486–1491.
15. Bourdin G, Schmitt B, Marvin Guy L, et al. Amplification and purification of T4-like Escherichia coli phages for phage therapy:from laboratory to pilot scale. Appl Environ Microbiol. 2014;80:1469–1476.
16. McCallin S, Sarker SA, Barretto C, et al. Safety analysis of a Russian phage cocktail:from metagenomic analysis to oral application in healthy human subjects. Virology. 2013;443:187–196.
17. Sarker SA, Sultana S, Reuteler G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations:a randomized trial in children from Bangladesh. EBioMedicine. 2016;4:124–137.•• A randomized, placebo-controlled clinical trial comparing two oral coliphage preparations, including a commercial Russian product, reporting lack of efficacy against acute diarrhea with microbiological failure analysis.
18. Sarker SA, Berger B, Deng Y, et al. Oral application of Escherichia coli bacteriophage:safety tests in healthy and diarrheal children from Bangladesh. Environ Microbiol. 2017;19:237–250.
19. Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz). 1987;35:569–583.
20. Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, et al. Clinical aspects of phage therapy. Adv Virus Res. 2012;83:73–121.
21. Pirnay JP, De Vos D, Verbeken G, et al. The phage therapy paradigm:prêt-à-porter or sur-mesure? Pharm Res. 2011;28:934–937.
22. Górski A, Międzybrodzki R, Weber-Dąbrowska B, et al. Phage therapy:combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol. 2016;7:1515.
23. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4:e4944.
24. Kvachadze L, Balarjishvili N, Meskhi T, et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol. 2011;4:643–650.
25. Fish R, Kutter E, Wheat G, et al. Bacteriophage treatment of intransigent diabetic toe ulcers:a case series. J Wound Care. 2016;25:S27–33.
26. Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology. 2012;434:222–232.
27. Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans:results of a phase I safety trial. J Wound Care. 2009;18:237–243.
28. Wright A, Hawkins CH, Anggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34:349–357.• First small but successful and well-documented controlled clinical trial describing phage therapy in human patients.
29. Parracho H, Burrowes BH, Enright MC, et al. The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genet Med. 2012;6:279–286.• Feasibility considerations of phage therapy in times of antibiotic resistance development by western pioneers in the field.
30. Henein A. What are the limitations on the wider therapeutic use of phage? Bacteriophage. 2013;3:e24872.
31. Reardon S. Phage therapy gets revitalized:the rise of antibiotic resistance rekindles interest in a century-old virus treatment. Nature. 2014;510:15–16.